Pivoting After SBIR Phase I: When Your Research Changes Your Business Model

In 2003, a small diagnostics company in San Jose won a $99,850 Phase I SBIR from the National Cancer Institute to develop a blood-based protein assay for early cancer detection. Eight months of bench work later, the founders had a problem: their assay wasn't sensitive enough for clinical oncology, but it performed unexpectedly well at detecting inflammatory biomarkers associated with autoimmune disease. The cancer-detection business plan they'd pitched to NIH was dead. The technology underneath it was very much alive.

The company pivoted. Its Phase II proposal reframed the core innovation -- a novel protein-capture surface chemistry -- around rheumatoid arthritis monitoring instead of cancer screening. NIH funded it. The $1 million Phase II award led to a licensed product that generated $14 million in revenue over its first three years on the market.

That story illustrates the SBIR program's most productive paradox: the government funds you to test a hypothesis, and the most valuable outcome is often the one where the hypothesis fails in a way that reveals something better. Roughly 55% of Phase I awardees never submit a Phase II proposal at all, according to data from the SBA's performance benchmark system. Some run out of time or ambition. But a meaningful fraction walk away because their Phase I results invalidated their original plan and they didn't know how to rebuild it. That's the group this article is for.

Why Phase I Pivots Are Structurally Inevitable

The SBIR program's architecture practically guarantees that pivots will happen. Phase I awards are small -- typically $150,000 to $275,000 depending on the agency -- and short, usually six to twelve months. Their explicit purpose is to establish technical feasibility. But feasibility is not a binary outcome. You don't just learn "it works" or "it doesn't." You learn how it works, where it works, and for whom it works. Those second-order findings are where pivots originate.

Consider the structural incentives. A founder writing a Phase I proposal has to project a commercialization pathway before the research has begun. That projection is necessarily speculative -- built on market intuition, prior literature, and conversations with potential customers, none of which have been stress-tested against actual technical performance data. Phase I is where speculation meets reality.

NIH's SBIR program office has acknowledged this dynamic openly, noting that Phase I is designed to "evaluate the scientific and technical merit and feasibility" of an approach, with the understanding that findings may reshape the commercial path forward. NSF's America's Seed Fund goes further: its Phase I awardee resources explicitly discuss "iterating or pivoting direction" as a normal part of the Phase I experience. The Defense Department's approach is more structured -- topic areas are tightly defined -- but even DoD program managers recognize that feasibility demonstrations frequently surface unforeseen applications.

In 1985, a six-person startup in San Diego called Qualcomm won its first SBIR Phase I from the National Science Foundation. The company had been doing contract R&D for the government, but the technical work funded by that early award revealed that its spread-spectrum technology had far more commercial potential in wireless communications than in military applications. Qualcomm pivoted from government services to consumer technology. By 2025, it had a market capitalization exceeding $180 billion. The pivot wasn't a failure of planning. It was the planning process working as designed.

Three Types of Pivot That Agencies Actually Respect

Not every pivot carries equal weight in a Phase II review. Understanding the taxonomy matters because the type of pivot determines how much narrative work your proposal needs to do.

The market pivot. Your technology works as described, but the highest-value customer isn't who you expected. This is the easiest pivot to defend because the core R&D hasn't changed. You're redirecting a proven capability toward a bigger or more accessible market. A cybersecurity tool built for defense networks that shows stronger product-market fit in financial services is a market pivot. Your Phase II technical objectives stay mostly the same; your commercialization plan gets a new market analysis section.

Eloqua launched as a messaging platform for financial services before discovering that its real market was lead generation software for enterprises -- a pivot that eventually led to an acquisition by Oracle for $871 million. In SBIR terms, this kind of pivot requires updating your commercialization plan's market analysis and customer discovery sections while keeping your technical objectives intact.

The application pivot. Your Phase I research reveals that the technology has a higher-value application in an adjacent field. A drone sensor package developed under a DoD topic might demonstrate commercial potential in precision agriculture. The underlying technology is the same; the use case has shifted. This requires more careful handling because the new application environment may introduce technical requirements, regulatory considerations, or manufacturing constraints that reviewers will expect you to address.

The technical pivot. During Phase I, you discover that a different technical approach solves the problem more effectively than what you proposed. This is the hardest pivot to execute within SBIR because it most directly challenges the "logical continuation" requirement. But it's also the most scientifically honest -- and agencies respect that. The key is demonstrating that the new approach emerged from your Phase I research rather than appearing out of nowhere. Show the data. Show the decision tree. Show why the original approach hit a wall and how the pivot preserves the program's investment in your work.

The critical distinction across all three types: your Phase II proposal must be a "logical continuation" of Phase I. That doesn't mean an identical continuation. A biosensor that demonstrated feasibility for a sensing mechanism in Phase I can absolutely target agricultural applications instead of clinical diagnostics in Phase II -- as long as the core technology is the same and the pivot is grounded in evidence gathered during the Phase I period.

Customer Discovery: The Infrastructure That Makes Pivots Credible

The single strongest move a Phase I awardee can make -- whether or not a pivot is on the horizon -- is to invest in structured customer discovery during Phase I. This is not optional supplementary work. It's the evidentiary scaffolding for your entire Phase II commercialization argument.

Federal agencies have built formal programs specifically for this purpose. NASA runs an SBIR I-Corps program requiring teams to evaluate commercial opportunity, determine product-market fit, and identify beachhead markets through hypothesis-driven interviews. The Department of Energy's Phase Shift program puts awardees through eight weeks and a minimum of 30 customer interviews, designed explicitly to help teams "iterate or pivot direction." NIH runs I-Corps at NIH on the same model.

NSF's version is the most demanding and most impactful. Phase I awardees accepted into NSF I-Corps conduct at least 100 customer discovery interviews over seven weeks, with a minimum commitment of 15 hours per week from each team member. Since the program launched in 2012, more than 3,000 teams have participated. Roughly half formed startups, and those companies have collectively raised $7 billion in private capital and over $1.7 billion in public funding, including approximately $540 million in SBIR/STTR awards.

For founders who can't commit to a formal program, there's a lower-friction option. Phase I awardees can request Technical and Business Assistance (TABA) funding -- up to $6,500 that doesn't come out of your R&D budget -- to pay for market research, customer interviews, IP assessments, and business strategy development. That's enough for 30 to 50 structured conversations with potential customers, which is enough to reshape your commercial thesis entirely.

The point of customer discovery isn't to confirm what you already believe. It's to generate the kind of first-party evidence that transforms a pivot from a red flag into a competitive advantage.

The Phone Call Most Founders Skip

Ask any experienced SBIR consultant to name the most underused resource in the program, and the answer is nearly unanimous: the program manager.

Founders from the venture world treat government grants like VC rounds -- close the deal, build in isolation, show up at demo day. That model is exactly wrong for SBIR. Program managers are domain experts, typically with PhDs and years of experience in their agency's mission area, who maintain portfolios of funded technologies and care about outcomes. Most of them actively want to hear from awardees about what's working and what's not.

If your Phase I results suggest a significant change in direction, contact your program manager before you write a single word of Phase II. This conversation accomplishes several things. It lets you gauge whether the agency would be receptive to a redirected effort. It gives you the chance to frame the pivot as responsive to your research findings rather than a sign of strategic confusion. And it may reveal opportunities you didn't know existed -- other topic areas, follow-on programs, or Phase III transition pathways that align better with your new direction.

For DoD awardees, this conversation is not just strategic -- it's procedurally expected. The Navy's Phase II guidelines explicitly require communication between the program office, the Phase I awardee, and the technical monitor before Phase II submission. The Army encourages awardees to discuss Phase II scope with their Contracting Officer's Representative. Submitting a dramatically different Phase II proposal without these conversations signals that you're not a collaborative partner -- exactly the wrong impression to make with an agency that may fund your work for years.

Rewriting the Phase II Commercialization Plan

The commercialization plan is where pivots come together or fall apart. Phase II awards are substantially larger -- from roughly $150,000-$300,000 in Phase I to as much as $1 million to $2 million in Phase II depending on the agency -- and reviewers scrutinize the commercial strategy with corresponding intensity.

NSF requires a four-section commercialization plan covering Market Opportunity, Company/Team, Product/Technology and Competition, and Finance and Revenue Model, along with a five-year cash flow pro forma. NIH expects a plan addressing market need, competitive landscape, IP strategy, and regulatory pathway. DoD agencies want a transition plan with specific military or government end users identified.

For a company that has pivoted, the plan must accomplish three things simultaneously:

Acknowledge the pivot explicitly. Do not pretend your Phase II commercialization strategy is what you always had in mind. Reviewers have read your Phase I proposal. They know. Instead, narrate the pivot as a story of disciplined discovery: "Phase I technical results demonstrated X, which revealed a larger commercial opportunity in Y." This positions the change as a strength -- evidence that you're responsive to data rather than dogmatic about your original plan.

Trace every claim to Phase I evidence. Each element of your revised commercialization plan should be traceable to work done during Phase I. Customer discovery interviews, letters of support from potential users in the new market, preliminary data in the new application domain -- this is the material that makes a pivot defensible. NSF allows up to five letters of support as an appendix. Use them all. Make sure at least two or three come from stakeholders in your new target market.

Own what you don't know yet. A pivot means entering territory where your assumptions are less validated. The strongest Phase II proposals from pivoted companies don't paper over this uncertainty -- they build it into the research plan. If you've shifted from clinical diagnostics to agricultural monitoring, your Phase II proposal should include specific aims related to validating performance in field conditions, understanding the agricultural supply chain, and engaging with the regulatory framework for agricultural technology. Reviewers want to see methodical rigor about the new direction, not just enthusiasm.

When the Pivot Exceeds Phase II's Boundaries

Sometimes Phase I results don't just suggest a new market or customer segment -- they reveal that the fundamental problem you're solving is different from the one the agency funded you to investigate. When the gap between your original topic and your actual findings is too wide, forcing the pivot into a Phase II proposal may not be credible.

The broader SBIR ecosystem provides alternatives. Most agencies issue solicitations with dozens of topic areas, and a technology proven feasible under one topic may directly address a different topic in the next cycle. DoD's open-topic SBIR accepts proposals that don't fit predefined categories. NSF's Phase I solicitation covers any area of science and engineering, making it inherently accommodating of technologies that have evolved beyond their original framing.

There's also the Direct to Phase II pathway, available at NSF, NIH, and several DoD components. If your Phase I work -- even if funded under a different topic -- has already demonstrated feasibility for a new application, a Direct to Phase II application lets you skip the Phase I stage and compete directly for the larger award.

One critical consideration: the SBA's Performance Benchmark Requirements track your Phase I to Phase II transition ratio. Companies with 21 or more Phase I awards over a five-year window must maintain a ratio of at least 0.25 -- one Phase II for every four Phase I awards. Those with 51 or more awards face a stricter threshold of 0.50. Abandoning Phase II submissions to start fresh with new Phase I proposals erodes that ratio and can eventually disqualify you from new awards. In most cases, adapting your Phase II proposal to reflect the pivot is strategically superior to walking away from it.

The Pivot as Competitive Advantage

The SBIR program distributes roughly $4 billion annually across 11 federal agencies. That money is meant to push technologies from the lab to the market. But markets shift, technical findings surprise, and the commercialization plan you wrote before your Phase I research began is almost certainly wrong in at least one important dimension.

The founders who convert Phase I awards into Phase II funding at the highest rates are not the ones whose original plans survived contact with reality. They're the ones who treated Phase I as a genuine experiment, documented what they learned, talked to their program managers, invested in customer discovery, and had the intellectual honesty to follow the data wherever it led.

A pivot isn't a liability in your Phase II proposal. Framed correctly and supported by evidence, it's the strongest possible proof that you're doing exactly what the SBIR program was designed to fund: turning early-stage research into commercial outcomes, even when the path gets rerouted along the way.

Granted helps founders track SBIR solicitations across all 11 federal agencies and match evolving technologies to the right opportunities -- especially when the plan has changed.